“…For example, PRSs were able to explain 6% of the variation in schizophrenia diagnostic rates, a considerable improvement compared to the variation explained by individual variants, which was less than 1% (Ripke et al, 2011). Other psychiatric phenotypes (e.g., de Moor et al, 2015; de Zeeuw et al, 2014; Hamshere et al, 2013a; 2013b; ISC, 2009; Ruderfer et al, 2013; Sklar et al, 2011) have demonstrated similar results using cumulative measures of genetic risk, including tobacco and other substance use phenotypes (Salvatore et al, 2014). PRSs for variants associated with CPD in the Tobacco and Genetics Consortium (TAG) meta-analysis (Tobacco and Genetics Consortium [TAG], 2010) significantly predicted tobacco use at ages 20 and 24 (Vrieze et al, 2012), and in another study, explained a small but significant proportion of the variation in number of drinks consumed per week (0.4–0.5%) and age of cannabis initiation (0.6–0.9%; Vink et al, 2014).…”